From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer

Commodore Capital sold 2,338,287 shares of Agios Pharmaceuticals in the fourth quarter. The quarter-end position value declined by $93.86 million as a result.

The Motley Fool • Feb 23, 2026

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash

Rock Springs Capital Management sold 159,379 Agios Pharmaceuticals shares in the fourth quarter; the estimated trade size was $5.59 million based on average fourth-quarter prices. Meanwhile, the quarter-end position value decreased by $16.72 million, reflecting both share sales and price movements.

The Motley Fool • Feb 17, 2026

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.

Zacks Investment Research • Feb 13, 2026

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 12, 2026

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026 Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026 $1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 2025 CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the fourth quarter and year ended December 31, 2025.

GlobeNewsWire • Feb 12, 2026

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 5, 2026

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m.

GlobeNewsWire • Jan 26, 2026

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow Company progressing early- and mid-stage pipeline in multiple high-value indications Clear path to profitability through the company's existing commercial presence in thalassemia and PK deficiency, with potential to achieve over $1 billion in peak global sales CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced its 2026 strategic priorities and key milestones anticipated during the year.

GlobeNewsWire • Jan 12, 2026